44 completed. 44 Phase 2, 21 Phase 1, 4 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 44 | Completed 44 |
| Phase 1 | 21 | Completed 21 |
| Phase 3 | 4 | Completed 4 |
Follow Advanced Cancer: new trials by email Literature Review of Advanced Cancer trials Research Report on Advanced Cancer
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of SNS-101 (Anti VISTA) Monotherapy and in Combination With Cemiplimab in Patients With Advanced Solid Tumors SNS-101 (anti-VISTA), Cemiplimab - Solid Tumor, Adult, Advanced Solid Tumor | Phase 1 / Phase 2 | Completed | Sensei Biotherapeutics, Inc. | 98 | 2023-05-31 | 2026-09-02 |
| RP-6306 in Patients With Advanced Cancer RP-6306, Gemcitabine, FOLFIRI Protocol - Advanced Cancer | Phase 2 | Completed | Canadian Cancer Trials Group | 28 | 2023-05-24 | 2026-02-06 |
| Study of Avutometinib (VS-6766) + Adagrasib in KRAS G12C NSCLC Patients avutometinib (VS-6766) and adagrasib - Non Small Cell Lung Cancer, KRAS Activating Mutation | Phase 1 / Phase 2 | Completed | Verastem, Inc. | 12 | 2022-08-01 | 2026-07-02 |
| Protreat-Trial: Prophylactic Antiemetic Treatment of Opioid-induced Nausea and Vomiting (OINV) in Palliative Care Palonosetron Hydrochloride, Placebo - Nausea, Vomiting | Phase 2 | Completed | Gerhild Becker | 30 | 2022-05-03 | 2025-03-19 |
| Phase 2 Basket Trial of Nab-sirolimus in Patients With Malignant Solid Tumors With Pathogenic Alterations in TSC1/TSC2 Genes (PRECISION 1) nab-sirolimus - Tumor, Tumor, Solid | Phase 2 | Completed | Aadi Bioscience, Inc. | 128 | 2022-03-10 | 2026-10-28 |
| Study of ASP7517 Alone and With Pembrolizumab in Participants With Advanced Solid Tumors Expressing WT1 Antigen ASP7517, Pembrolizumab - Advanced Malignancies, Advanced Cancer | Phase 1 / Phase 2 | Completed | Astellas Pharma Global Development, Inc. | 24 | 2021-11-11 | 2025-08-08 |
| Lenvatinib in Locally Advanced Invasive Thyroid Cancer LENVATINIB - Differentiated Thyroid Cancer, Advanced Cancer | Phase 2 | Completed | Massachusetts Eye and Ear Infirmary | 29 | 2021-03-09 | 2026-06-25 |
| Cemiplimab in AlloSCT/SOT Recipients With CSCC Cemiplimab, Everolimus, Sirolimus - Cutaneous Squamous Cell Carcinoma, Advanced Cancer | Phase 1 / Phase 2 | Completed | Dana-Farber Cancer Institute | 12 | 2020-11-03 | 2025-04-23 |
| LY3214996 +/- HCQ in Pancreatic Cancer Hydroxychloroquine Sulfate, LY3214996 - Pancreatic Cancer, Advanced Cancer | Phase 2 | Completed | Kimberly Perez, MD | 52 | 2020-05-27 | 2025-02-12 |
| Combination of Nivolumab Plus Relatlimab in Patients With Advanced or Metastatic Soft-tissue Sarcoma: a Proof-of-concept Randomized Phase II Study Association of Nivolumab + Relatlimab, Nivolumab - Soft Tissue Sarcoma Adult, Advanced Cancer | Phase 2 | Completed | Institut Bergonié | 68 | 2020-02-27 | 2026-04-21 |
| Pembrolizumab in Biliary Tract Cancer Pembrolizumab, Cisplatin, Gemcitabine - Biliary Tract Cancer, Metastatic Cancer | Phase 2 | Completed | European Organisation for Research and Treatment of Cancer - EORTC | 50 | 2020-01-07 | 2023-11-03 |
| Study to Evaluate the Efficacy/Safety of IPI-549 in Combination With Nivolumab in Patients With Advanced Urothelial Carcinoma (MARIO-275) IPI-549 (eganelisib), Nivolumab, Placebos - Bladder Cancer, Urothelial Carcinoma | Phase 2 | Completed | Infinity Pharmaceuticals, Inc. | 49 | 2019-09-25 | 2022-11-25 |
| Ketamine or Placebo in Patients With Major Depression and Advanced Cancer Ketamine, Placebo - Major Depressive Disorder, Advanced Cancer | Phase 1 / Phase 2 | Completed | Instituto Nacional de Cancerologia de Mexico | 19 | 2019-09-19 | 2023-09-28 |
| An Investigational Immunotherapy Study of BMS-986288 Alone and in Combination With Nivolumab in Advanced Solid Cancers BMS-986288, Nivolumab, Regorafenib - Advanced Cancer | Phase 1 / Phase 2 | Completed | Bristol-Myers Squibb | 219 | 2019-09-06 | 2026-01-20 |
| A Study of Pembrolizumab in Patients With Advanced Gynaecological Clear Cell Cancer Pembrolizumab - Clear Cell Tumor, Gynecologic Cancer | Phase 2 | Completed | University College, London | 48 | 2019-02-18 | 2026-09-22 |
| DM-CHOC-PEN for Brain Tumors in AYA Subjects DM-CHOC-PEN - Advanced Cancer, Brain Metastases | Phase 2 | Completed | DEKK-TEC, Inc. | 20 | 2019-01-01 | 2022-11-08 |
| A Study of BMS-986205 Alone and in Combination With Nivolumab in Chinese Patients With Advanced Malignant Solid Tumors BMS-986205, Nivolumab - Advanced Cancer | Phase 1 / Phase 2 | Completed | Bristol-Myers Squibb | 12 | 2018-12-31 | 2022-02-28 |
| Evaluation of Ocoxin-Viusid® in Advanced Pancreatic Adenocarcinoma Ocoxin-Viusid® - Adenocarcinoma of the Pancreas, Pancreatic Cancer | Phase 2 | Completed | Catalysis SL | 30 | 2018-10-30 | 2023-03-28 |
| Dose Escalation and Expansion Study of FLX475 Monotherapy and in Combination With Pembrolizumab FLX475 (tivumecirnon), pembrolizumab (KEYTRUDA®) - Advanced Cancer | Phase 1 / Phase 2 | Completed | RAPT Therapeutics, Inc., a member of the GSK plc group of companies | 323 | 2018-09-25 | 2026-09-03 |
| Lenvatinib and Eribulin in Advanced Soft Tissue Sarcoma Eribulin, Lenvatinib - Leiomyosarcoma, Liposarcoma | Phase 1 / Phase 2 | Completed | National Taiwan University Hospital | 30 | 2018-07-12 | 2025-12-05 |
Showing 20 of 44. Sign in to see all of them.
Carcinoma, Non-Small-Cell Lung (8) · Neoplasm Metastasis (6) · Neoplasms (5) · Pancreatic Neoplasms (5) · Carcinoma, Transitional Cell (3) · Sarcoma (3) · Uterine Cervical Neoplasms (3) · Breast Neoplasms (2) · Head and Neck Neoplasms (2) · Melanoma (2) · Nausea (2) · Urinary Bladder Neoplasms (2) · Vomiting (2) · Biliary Tract Neoplasms (1) · Brain Neoplasms (1)
Neoplasms (17) · Neoplasms by Site (16) · Pathological Conditions, Signs and Symptoms (11) · Neoplasms by Histologic Type (9) · Bronchial Neoplasms (8) · Carcinoma, Bronchogenic (8) · Lung Diseases (8) · Respiratory Tract Diseases (8) · Respiratory Tract Neoplasms (8) · Thoracic Neoplasms (8) · Lung Neoplasms (7) · Digestive System Diseases (6) · Digestive System Neoplasms (6) · Neoplastic Processes (6) · Pathologic Processes (6)
Nivolumab (10) · Ipilimumab (5) · linrodostat (4) · pembrolizumab (4) · Gemcitabine (3) · relatlimab (3) · spartalizumab (3) · cemiplimab (2) · lenvatinib (2) · ARRY-334543 (1) · Axitinib (1) · BMS-813160 (1) · Carboplatin (1) · Cetuximab (1) · Cisplatin (1)
Bristol-Myers Squibb (8) · Eli Lilly and Company (2) · M.D. Anderson Cancer Center (2) · Aadi Bioscience, Inc. (1) · Agenus Inc. (1) · Array BioPharma (1) · Astellas Pharma Global Development, Inc. (1) · Bayer (1) · CASI pharmaceuticals, Inc. (1) · Canadian Cancer Trials Group (1) · Cantonal Hospital of St. Gallen (1) · Catalysis SL (1) · Catherine Naseef Hunter (1) · Centre Leon Berard (1) · DEKK-TEC, Inc. (1)
United States (26) · Spain (10) · Canada (9) · Italy (9) · France (8) · Australia (7) · Germany (6) · United Kingdom (5) · Poland (4) · Chile (3) · China (3) · Puerto Rico (3) · Switzerland (3) · Argentina (2) · Finland (2)
Ali Baghian, MD (1) · Catherine N Hunter, Ass. lecturer (1) · Eduardo Bruera, MD (1) · Eric Chen (1) · Florian Strasser, PD Dr. MD (1) · Gerhild Becker, Prof. Dr. med. (1) · Glenn J Hanna, MD (1) · Gregory Randolph, MD (1) · Halle Zhang, PhD, RN (1) · Kimberly Perez, MD (1)
PMID 19951879, PMID 23589315, PMID 23690414, PMID 24106841, PMID 26644411, PMID 27148765, PMID 28065465, PMID 32379269, PMID 32792420, PMID 33109737, PMID 33148673, PMID 33152282, PMID 33477979, PMID 36129471, PMID 36328377, PMID 36821617, PMID 37948895, PMID 37988648, PMID 38252908, PMID 39913118, PMID 41719493
2015 (2), 2018 (2), 2016 (1), 2017 (1), 2019 (1), R01NR010162 (1)